Pseudomonas Aeruginosa is a soil bacterium that causes diseases in a plant, animal and humans. It has an antibiotic resistance property because of which it creates life-threatening conditions that are difficult to treat. Pseudomonas Aeruginosa is one of the key reasons for having surgical site infection and hospital-acquired infection in patient hospitalized for a longer period. It is estimated that around 1.7 million patient suffers from hospital acquire infection and 99,000 dies each year from the same.
According to MRFR analysis, the global Pseudomonas Aeruginosa Treatment Market Size is expected to register a CAGR of ~7% during the forecast period of 2019 to 2025 and is likely to be valued at USD 7.5 billion in 2025.
The growth of the global Pseudomonas Aeruginosa treatment market is determined by numerous factors such as an increasing number of surgeries, a growing geriatric population, increasing cases of hospital-acquired infection, which is directly responsible for increasing global Pseudomonas Aeruginosa treatment market. However, the side effects associated with the medication and lack of awareness about the disease caused due to Pseudomonas Aeruginosa are likely to hamper the growth of the global Pseudomonas Aeruginosa treatment market during the forecast period.
· Gilead Sciences Inc
· Lupin Pharmaceuticals
· Teva Pharmaceutical Industries Ltd
· Novartis AG
· PARI Medical Holding GmbHb
· Humanigen Inc
· Merck & Co
· AmpliPhi Biosciences Corp
· Bristol-Myers Squibb Co
· Aradigm Corp
· The global Pseudomonas Aeruginosa Treatment market has been segmented based on medication, route of administration, and distribution channel.
· The market, based on medication, has been divided into monotherapy and combination therapy.
· The global Pseudomonas Aeruginosa treatment market on the basis of route of administration has been segregated into nasal, oral, and intravenous.
· The distribution channel segment of the market consists of hospital pharmacies, retail pharmacies, and online pharmacies.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing number of surgical sites infection and increasing demand for antibiotics to treat the same drives the market growth during the forecasted period.
The European Pseudomonas Aeruginosa treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Pseudomonas Aeruginosa treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rising geriatric population and the presence of a large patient pool, the market in Asia-Pacific is expected to be the fastest-growing. The Pseudomonas Aeruginosa Treatment market in the Middle East & Africa has been divided into the Middle East and Africa.